GILEAD Oncology - Live Broadcast to Explore a Newly Approved Treatment Option Available for Patients with Pretreated HR+/HER2-negative Metastatic Breast Cancer
Meeting Host
GILEAD OncologyDescription
In an upcoming live broadcast, watch Hope S. Rugo, MD, FASCO and Joyce O'Shaughnessy, MD provide an overview of the unmet needs for patients with HR-positive, HER2-negative metastatic breast cancer who were previously treated with endocrine therapy. They will also discuss data on efficacy and safety of a newly approved treatment option in this setting, and will also touch on identification of patients with HR-positive, HER2-negative metastatic breast cancer who may be suitable for this regimen, as well as considerations regarding dosage, administration, and potential adverse event management.
To obtain clinical expert insights and learn about how this new therapy may impact your patients and your practice, watch the live broadcast on Thursday, March 30th at 6:00pm EDT/3:00pm PDT and 8:00pm EDT/5:00pm PDT. To register for the event, visit https://studio.mjhassoc.com/reach/HER2neg-mBC#.
This promotional program is sponsored by, and the speakers are presenting on behalf of, Gilead Sciences, Inc. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.
